Shirish Gadgeel, MD
Evidence is increasing that blood-based biomarkers have predictive utility in advanced non–small cell lung cancer (NSCLC). Going further, blood-based next-generation sequencing (NGS) appears to have clinical utility in selecting targeted treatment in this setting. The performance of blood-based biomarkers in the setting of advanced NSCLC was the subject of several presentations at the 2019 ESMO Congress, 2 of which are summarized here.
... to read the full story